Department of Neurology, Keio University School of Medicine, Tokyo, 160-8582, Japan; Department of Neurology, Tokyo Dental College Ichikawa General Hospital, Chiba, 272-0513, Japan.
Department of Neurology, Keio University School of Medicine, Tokyo, 160-8582, Japan.
Neurosci Res. 2021 Nov;172:80-86. doi: 10.1016/j.neures.2021.03.010. Epub 2021 Apr 2.
Migraine sufferers often exhibit photophobia and physical hypoactivity in the postdrome and interictal periods, for which no effective therapy currently exists. Cortical spreading depolarization (CSD) is a neural phenomenon underlying migraine aura. We previously reported that CSD induced trigeminal sensitization, photophobia, and hypomobility at 24 h in mice. Here, we examined the effects of CSD induction on light sensitivity and physical activity in mice at 48 h and 72 h. Trigeminal sensitization was absent at both time points. CSD-subjected mice exhibited significantly less ambulatory time in both light (P = 0.0074, the Bonferroni test) and dark (P = 0.0354, the Bonferroni test) zones than sham-operated mice at 72 h. CSD-subjected mice also exhibited a significantly shorter ambulatory distance in the light zone at 72 h than sham-operated mice (P = 0.0151, the Bonferroni test). Neurotropin® is used for the management of chronic pain disorders, mainly in Asian countries. The CSD-induced reductions in ambulatory time and distance in the light zone at 72 h were reversed by Neurotropin® at 0.27 NU/kg. Our experimental model seems to recapitulate migraine-associated clinical features observed in the postdrome and interictal periods. Moreover, Neurotropin® may be effective in ameliorating postdromal/interictal hypoactivity, especially in a light environment.
偏头痛患者在发作后期和发作间期经常表现出畏光和身体活动减少,但目前尚无有效的治疗方法。皮质扩散性抑制(CSD)是偏头痛先兆的神经现象。我们之前报道过,CSD 可诱导三叉神经敏化、畏光和在 24 小时后小鼠的活动减少。在这里,我们研究了 CSD 诱导在 48 小时和 72 小时对小鼠光敏感性和身体活动的影响。在这两个时间点,三叉神经敏化均不存在。CSD 组小鼠在光照(P = 0.0074,Bonferroni 检验)和黑暗(P = 0.0354,Bonferroni 检验)区域的活动时间明显少于假手术组小鼠,在 72 小时。CSD 组小鼠在光照区的活动距离也明显短于假手术组小鼠(P = 0.0151,Bonferroni 检验)。Neurotropin® 用于治疗慢性疼痛疾病,主要在亚洲国家使用。在 72 小时时,Neurotropin® 可逆转 CSD 诱导的光区活动时间和距离的减少,用量为 0.27 NU/kg。我们的实验模型似乎再现了偏头痛在发作后期和发作间期观察到的相关临床特征。此外,Neurotropin® 可能有效改善发作后期/发作间期活动减少,尤其是在光环境中。